In vitro modulatory effects of Terminalia arjuna, arjunic acid, arjunetin and arjungenin on CYP3A4, CYP2D6 and CYP2C9 enzyme activity in human liver microsomes

Toxicology Reports

Volumn 2, Issue , 2015, Pages 806-816

  Varghese, Alice ^a   Savai, Jay ^a   Pandita, Nancy ^b   Gaud, Ram ^a  

^a SVKM s Narsee Monjee Institute of Management Studies   (India)

^b NMIMS UNIVERSITY   (India)

Author keywords

CYP enzyme; CYP inhibition; Herb drug interactions; Human liver microsomes; Terminalia arjuna; Toxicity

Indexed keywords

ALCOHOL; ARJUNETIN; ARJUNGENIN; ARJUNIC ACID; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DEXTROMETHORPHAN; DEXTRORPHAN; DICLOFENAC; ISOSORBIDE DINITRATE; PHENACETIN; PLANT MEDICINAL PRODUCT; QUINIDINE; SEROTONIN; SULFAPHENAZOLE; TERMINALIA ARJUNA EXTRACT; TESTOSTERONE; UNCLASSIFIED DRUG; WATER;

ARTICLE; CHEMICAL STRUCTURE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME KINETICS; HIGH PERFORMANCE THIN LAYER CHROMATOGRAPHY; HUMAN; HUMAN CELL; IC50; INHIBITION CONSTANT; INHIBITION KINETICS; LIVER MICROSOME; TERMINALIA ARJUNA; TIME-DEPENDENT INHIBITION;

EID: 84930483112     PISSN: 22147500     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxrep.2015.02.008     Document Type: Article

References (27)

1. Aiming Y.U., Haining R.L. Comparative contribution to dextromethorphan metabolism by cytochrome P450 isoforms in vitro: can dextromethorphan be used as a dual probe for both CYP2D6 and CYP3A activities. Drug Metab. Dispos. 2001, 29(11):1514-1520.
2. Andrew J.S., et al. Regulation of testosterone hydroxylation by rat liver microsomal cytochrome P-450. Arch. Biochem. Biophys. 1987, 255:27-41.
3. Dambal A.A., Bhagwat D.A., Khadbadi S.S. Pharmacognostic studies of the Terminalia arjuna bark. Int. J. Chem. Pharm. Sci. 2014, 2(5):837-840.
4. Divya K., et al. Terminalia arjuna in coronary artery disease: ethnopharmacology, pre-clinical, clinical and safety evaluation. J. Ethnopharmacol. 2014, 155(2):1029-1045.
5. Dwivedi S. Terminalia arjuna Wight and Arn. - a useful drug for cardiovascular disorders. J. Ethnopharmacol. 2007, 114:114-129.
6. Dwivedi S., et al. Cardioprotective effects of certain indigenous drugs in myocardial ischemia in rabbits. Indian J. Exp. Biol. 1988, 26:969-975.
7. Fand S., Zhang H. In vitro evaluation of reversible and irreversible cytochrome P450 inhibition: current status on methodologies and their utility for predicting drug-drug interactions. AAPS J. 2008, 10:410-424.
8. Fasinu P.S., Bouic P.J., Rosenkranz B. An overview of the evidence and mechanisms of herb-drug interactions. Front. Pharmacol. 2012, 3:1-19.
9. Guidance for Industry Drug Interactions Studies: Study Design, Data Analysis and Implications for Dosing and Labeling 2006, September, http://www.fda.gov/cder, http://www.fda.gov./cder/guidance/6695dft.pdf.
10. Khanna A.K., et al. Terminalia arjuna: an ayurvedic cardiotonic regulates lipid metabolism in hyperlipidemic rats. Phytother. Res 1996, 10:663-666.
11. Liu Y., et al. Influence of ginsenoside Rh1 and F1 on human cytochrome P450 enzymes. Planta Med. 2006, 72:126-131.
12. Maulik S.K., Katiyar C.K. Terminalia arjuna in cardiovascular diseases: making the transition from traditional to modern medicine in India. Curr. Pharm. Biotechnol. 2010, 11:855-860.
13. Maulik S.K., Talwar K.K. Therapeutic potential of Terminalia arjuna in cardiovascular disorders. Am. J. Cardiovasc. Drugs 2012, 12:157-163.
14. Michael M.J., et al. Approaches to the rational design of enzyme inhibitors. Burg. Med. Chem. Drug Discov. 2001, 1:715-779.
15. Obach S.R. Inhibition of human cytochrome P450 enzymes by constituents of St. John's Wort, an herbal preparation used in the treatment of depression. J. Pharmacol. Exp. Ther. 2000, 294:88-95.
16. Pawar R.S. Effect of oleanane triterpenoids from Terminalia arjuna: a cardioprotective drug on the process of respiratory oxyburst. Phytomedicine 2005, 12:391-393.
17. Subramaniam S., et al. Anti-hyperlipidemic and antioxidant potential of different fractions of Terminalia arjuna Roxb. bark against PX-407 induced hyperlipidemia. Indian J. Exp. Biol. 2011, 49:282-288.
18. Sumitra M., et al. Experimental myocardial necrosis in rats: role of arjunolic acid on platelet aggregation, coagulation and antioxidant status. Mol. Cell Biochem. 2001, 224:135-142.
19. Stephen F., et al. In vitro evaluation of reversible and irreversible cytochrome P450 inhibition: current status on methodologies and their utility for predicting drug-drug interactions. AAPS J. 2008, 10:410-423.
20. Steven A.W., Jeffrey C.S. The human hepatic cytochrome P450 involved in drug metabolism. Crit. Rev. Toxicol. 1992, 22:1-21.
21. Takahashi S., et al. Hypotensive effects in rats of hydrophilic extract from Terminalia arjuna containing tannin-related compounds. Phytother. Res. 1997, 1:424-427.
22. Tang J., et al. Inhibition of cytochrome P450 enzymes by rhein in rat liver microsomes. Phytother. Res. 2009, 23:159-164.
23. Ushijima K., et al. Cranberry juice suppressed the diclofenac metabolism by human liver microsomes, but not in healthy human subjects. Br. J. Clin. Pharm. 2009, 68(2):194-200.
24. Varghese A., et al. In vitro and in vivo evaluation of CYP1A interaction potential of Terminalia arjuna bark. Indian J. Pharm. Sci. 2014, 76:138-147.
25. Yan P., et al. In vitro modulatory effects of Andrographis paniculata, Centella asiatica and Orthosiphon stamineus on cytochrome P450 2C19 (CYP2C19). J. Ethnopharmacol. 2011, 133:881-887.
26. Ho P.C., Saville D.J., Wanvimolruk S. Inhibition of human CYP3A4 by grapefruit flavonoids, furanocoumarins and related compounds. J. Pharm. Pharm. Sci. 2001, 4:217-227.
27. Ponnusankar S., Pandit S., Babu R., et al. Cytochrome P450 inhibitory potential of Triphala-Rasayana from Ayurveda. J. Ethnopharmacol. 2011, 133:120-125.